This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- 6-O-benzylguanine
- DrugBank Accession Number
- DB11919
- Background
6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for 6-O-benzylguanine (DB11919)
- Weight
- Average: 241.2486
Monoisotopic: 241.096359999 - Chemical Formula
- C12H11N5O
- Synonyms
- O(6)-Benzylguanine
- O6-benzylguanine
- External IDs
- NSC-637037
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with 6-O-benzylguanine. Abametapir The serum concentration of 6-O-benzylguanine can be increased when it is combined with Abametapir. Abatacept The metabolism of 6-O-benzylguanine can be increased when combined with Abatacept. Abiraterone The serum concentration of 6-O-benzylguanine can be increased when it is combined with Abiraterone. Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with 6-O-benzylguanine. Acenocoumarol The metabolism of 6-O-benzylguanine can be decreased when combined with Acenocoumarol. Acetaminophen The metabolism of 6-O-benzylguanine can be decreased when combined with Acetaminophen. Acetazolamide Acetazolamide may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy. Acyclovir The metabolism of 6-O-benzylguanine can be decreased when combined with Acyclovir. Adalimumab The serum concentration of 6-O-benzylguanine can be decreased when it is combined with Adalimumab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Imidazopyrimidines
- Sub Class
- Purines and purine derivatives
- Direct Parent
- Hypoxanthines
- Alternative Parents
- Aminopyrimidines and derivatives / Alkyl aryl ethers / Benzene and substituted derivatives / Imidazoles / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 01KC87F8FE
- CAS number
- 19916-73-5
- InChI Key
- KRWMERLEINMZFT-UHFFFAOYSA-N
- InChI
- InChI=1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)
- IUPAC Name
- 6-(benzyloxy)-9H-purin-2-amine
- SMILES
- NC1=NC(OCC2=CC=CC=C2)=C2N=CNC2=N1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 4578
- PubChem Substance
- 347828250
- ChemSpider
- 4417
- BindingDB
- 5491
- ChEMBL
- CHEMBL407874
- ZINC
- ZINC000005425464
- PDBe Ligand
- OBG
- PDB Entries
- 3kzz
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System 1 2 Completed Treatment Anaplastic Glioma / Glioblastoma Multiforme (GBM) 1 2 Completed Treatment Central Nervous System Neoplasm 2 2 Completed Treatment Colorectal Cancer 1 2 Completed Treatment Melanoma 1 2 Completed Treatment Multiple Myeloma and Plasma Cell Neoplasm 1 2 Completed Treatment Recurrent Adult Brain Neoplasm 1 2 Completed Treatment Sarcomas 1 2 Not Yet Recruiting Treatment Adult Glioblastoma / Glioblastoma Multiforme (GBM) / Supratentorial Glioblastoma / Supratentorial Gliosarcoma 1 2 Terminated Treatment Astrocytoma / Glioma / Mixed Oligodendroglioma-Astrocytoma / Oligodendroglioma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.63 mg/mL ALOGPS logP 2.09 ALOGPS logP 1.71 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 8.98 Chemaxon pKa (Strongest Basic) 4.71 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 89.71 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 67.62 m3·mol-1 Chemaxon Polarizability 24.63 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0006-9511000001-e6a03ce9bd4d7464a377
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME: Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26;50(9):1385-9. [Article]
Drug created at October 20, 2016 21:00 / Updated at June 12, 2020 16:53